Genomic Variation and the Inherited Basis of Common Disease
Share this article Share 'As time goes on, it's probably going to be the case that the majority of cancers will have some kind of targeted therapy. They just carry on growing fast.
At a low concentration, healthy cancer human genetic disease are strong enough to survive the treatment while at the same time the cancer cells that are bad at repairing their genetic make-up are destroyed. Scan: Cancer human genetic disease drug undergoing medical trials in London works by attacking the breast cancer cells' inability to repair their own damaged genetic structure file picture Prof Ashworth added: 'At this concentration, all the mutant cells are killed but the normal cells are not really touched.
Is this cancer's 'penicillin moment'? Gene targeting drug could herald 'end game' for disease
Prof Ashworth said: 'We are in the 21st century, we've got the human genome sequence, and we're cancer human genetic disease treating cancer with medieval treatments. There is nothing clever about it at all.
Just as the discovery of penicillin opened the floodgates to an array of bacteria-fighting antibiotics, our ever-growing knowledge about DNA and its cancer human genetic disease and flaws is leading to the production of many more drugs like PLX This is about identifying the cancer, knowing what its changes are and being able to follow it in ways we could never have dreamt of before. Professor Mark Stratton, director of the Wellcome Trust Sanger Institute believes we may have reached the 'end game' for understanding cancer A trial on cancer patients, including some Britons, is underway, and, if successful, the drug could be on the market in as little as a year. GlaxoSmithKline is cancer human genetic disease a similar compound.
Institute director Professor Mike Stratton said the research meant it might soon be possible to treat and even create drugs which can prevent cancer completely. Tonight's programme also features a medical trial of a drug to cure cystic cancer human genetic disease using a similar method of gene therapy, which could be available on the NHS in just five years.
It works by replacing the faulty gene that causes cystic fibrosis with a healthy manmade version, which is suspended in a fatty liquid and inhaled via a nebuliser. He said: 'Around that time we should get a feeling of whether that trial, for the first time in the world, has shown if patients can actually get better clinically.